NASDAQ$ANTX
AN2 Therapeutics Inc · Q4 2026 earnings
Q4 2026 earnings · · After market close · Investor relations
Briefing
AN2 Therapeutics reported fiscal Q4 2026 no revenue, a net loss of $10.0M, and diluted loss per share of $0.29.
For the three months ended March 31, 2026 (fiscal Q4), AN2 had no product revenue and operating expenses of $10.6 million (R&D $6.7M, G&A $3.8M). Net loss attributable to common stockholders was $10.0 million ($0.29 loss per share) versus $10.6 million and $0.35 loss. Interest income $0.5 million.
- Pre-revenue antibiotic development stage.
- R&D $6.7M on epetraborole programs.
- Net loss $10.0M; EPS loss $0.29.
- Cash resources support clinical trials.
- Fiscal year-end Q4 period.
Headline financials
Revenue & EPS history
AN2 Therapeutics · Revenue · Quarterly
$0
Forward guidance
Clinical trial milestones and partnership options discussed.
Tailwinds
- Loss roughly flat YoY.
- Interest income on cash.
Headwinds
- No revenue; ongoing cash burn.
- Regulatory and trial execution risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2026
+8.9%
Avg return
Earnings day
+14.4%
Avg return
5 days after
-1.6%
Avg return
30 days after
47%
9 / 19 earnings
Positive
+75.2%
Q2 2021
Best reaction
-6.2%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.9% | +0.8% | -5.7% | |
| Q3 2025 | -4.3% | -5.1% | +1.7% | |
| Q2 2024 | +1.9% | +6.2% | +21.3% | |
| Q2 2025 | +0.0% | +6.2% | +21.3% | |
| Q1 2025 | -1.7% | -1.7% | -10.7% | |
| Q4 2024 | -2.4% | -9.3% | -16.7% | |
| Q3 2024 | -5.7% | -5.7% | +34.9% | |
| Q1 2024 | -3.4% | -3.4% | -15.3% | |
| Q4 2023 | +16.8% | +5.6% | -28.0% | |
| Q3 2023 | -6.2% | +4.5% | +23.2% | |
| Q2 2023 | +2.8% | +5.4% | +90.1% | |
| Q1 2023 | +0.4% | +46.2% | +48.5% | |
| Q4 2022 | +1.8% | +4.8% | -17.0% | |
| Q3 2021 | -3.5% | -3.3% | -41.4% | |
| Q3 2022 | -3.5% | -3.3% | -41.4% | |
| Q2 2022 | +75.2% | +95.8% | -14.6% | |
| Q2 2021 | +75.2% | +95.8% | -14.6% | |
| Q4 2021 | +14.2% | +16.9% | -32.9% | |
| Q1 2022 | +14.2% | +16.9% | -32.9% | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro